Low Dose Teclistamab in Newly Diagnosed Multiple Myeloma Patients

This single-arm, open-label study aims to determine the efficacy and safety of low-dose, limited-duration teclistamab as a consolidation scheme in newly diagnosed multiple myeloma (NDMM) patients.

Trial Details

NCT ID
NCT06758375
Phase
PHASE2
Sponsor
Hospital Universitario Dr. Jose E. Gonzalez
Status
RECRUITING
Cancer Type
Newly Diagnosed Multiple Myeloma
Interventions
  • Low-dose teclistamab
Locations (sample)
  • Monterrey, Nuevo León, Mexico|25.68435,-100.31721

Key Eligibility Criteria

  • ≥18 years of age.
  • Newly diagnosed multiple myeloma.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status Score of 0 or 1.
  • Women of childbearing potential must have a negative serum pregnancy test prior to starting treatment and agree to use a highly effective method of…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Newly Diagnosed Multiple Myeloma Trials on Trialify →